Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Diacerein: a potential therapeutic drug for periodontal disease.

Huang RY, Lu SH, Su KW, Chen JK, Fang WH, Liao WN, Chen SY, Shieh YS.

Med Hypotheses. 2012 Aug;79(2):165-7. doi: 10.1016/j.mehy.2012.04.024. Epub 2012 May 13.

PMID:
22583561
2.

Perspective of cytokine regulation for periodontal treatment: fibroblast biology.

Takashiba S, Naruishi K, Murayama Y.

J Periodontol. 2003 Jan;74(1):103-10. Review.

PMID:
12593604
3.

The impact of new technologies to diagnose and treat periodontal disease. A look to the future.

Williams RC, Beck JD, Offenbacher SN.

J Clin Periodontol. 1996 Mar;23(3 Pt 2):299-305.

PMID:
8707994
4.

Cytokine expression in periodontal health and disease.

Okada H, Murakami S.

Crit Rev Oral Biol Med. 1998;9(3):248-66. Review.

PMID:
9715365
5.

The role of inflammatory mediators in the pathogenesis of periodontal disease.

Page RC.

J Periodontal Res. 1991 May;26(3 Pt 2):230-42. Review.

PMID:
1679130
6.

Pathogenesis of periodontitis: role of cytokines in host response.

Deo V, Bhongade ML.

Dent Today. 2010 Sep;29(9):60-2, 64-6; quiz 68-9. Review.

PMID:
20973418
7.

The role of IL-6 in the pathogenesis of periodontal disease.

Irwin CR, Myrillas TT.

Oral Dis. 1998 Mar;4(1):43-7. Review.

PMID:
9655045
8.

Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists.

Delima AJ, Karatzas S, Amar S, Graves DT.

J Infect Dis. 2002 Aug 15;186(4):511-6. Epub 2002 Jul 24.

PMID:
12195378
9.

Periodontal manifestations of systemic disease.

Kinane DF, Marshall GJ.

Aust Dent J. 2001 Mar;46(1):2-12. Review.

10.

Studies on synthesis, stability, release and pharmacodynamic profile of a novel diacerein-thymol prodrug.

Dhaneshwar S, Patel V, Patil D, Meena G.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):55-61. doi: 10.1016/j.bmcl.2012.11.016. Epub 2012 Nov 16.

PMID:
23218603
11.

The interplay of lipopolysaccharide-binding protein and cytokines in periodontal health and disease.

Ren L, Jiang ZQ, Fu Y, Leung WK, Jin L.

J Clin Periodontol. 2009 Aug;36(8):619-26. doi: 10.1111/j.1600-051X.2009.01436.x. Epub 2009 Jun 26.

PMID:
19558463
12.

Cellular immunity and hypersensitivity as components of periodontal destruction.

Seymour GJ, Gemmell E, Kjeldsen M, Yamazaki K, Nakajima T, Hara K.

Oral Dis. 1996 Mar;2(1):96-101. Review.

PMID:
8957943
13.

Diacerein has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast--comparison to its effects on osteoarthritic chondrocytes.

Alvarez-Soria MA, Herrero-Beaumont G, Sánchez-Pernaute O, Bellido M, Largo R.

Rheumatology (Oxford). 2008 May;47(5):627-33. doi: 10.1093/rheumatology/ken116. Epub 2008 Mar 27.

PMID:
18375401
14.

Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption.

Tamura T, Shirai T, Kosaka N, Ohmori K, Takafumi N.

Eur J Pharmacol. 2002 Jul 12;448(1):81-7.

PMID:
12126975
15.
17.

Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone.

Pelletier JP, Lajeunesse D, Reboul P, Mineau F, Fernandes JC, Sabouret P, Martel-Pelletier J.

J Rheumatol. 2001 Apr;28(4):814-24.

PMID:
11327257
18.

Pharmacologic management of periodontal diseases using systemically administered agents.

Mariotti A, Monroe PJ.

Dent Clin North Am. 1998 Apr;42(2):245-62. Review.

PMID:
9597336
19.
20.

Effect of metronidazole and modulation of cytokine production on human periodontal ligament cells.

Rizzo A, Paolillo R, Guida L, Annunziata M, Bevilacqua N, Tufano MA.

Int Immunopharmacol. 2010 Jul;10(7):744-50. doi: 10.1016/j.intimp.2010.04.004. Epub 2010 Apr 22.

PMID:
20399284

Supplemental Content

Support Center